Use of Renin-Angiotensin-Aldosterone System Inhibitors and Severe COVID-19 Outcomes in Patients with Hypertension: A Nationwide Cohort Study
OPEN Diabetes & metabolism journal | 23 Feb 2021
JH Bae, SK Choi, NH Kim, J Lee and SG Kim
Abstract
Angiotensin-converting enzyme 2 facilitates the entry of severe acute respiratory syndrome coronavirus 2 into the human body. We investigated the association of renin-angiotensin-aldosterone system (RAAS) inhibitor use with severe coronavirus disease 2019 (COVID-19) outcomes in hypertensive patients.
comments powered by Disqus
* Data courtesy of Altmetric.com